EpilepsyGTx and Viralgen Unite to Propel Gene Therapy for Epilepsy Toward Clinical Trials

Advancement in Epilepsy Treatment: A Collaboration for Hope

In a significant stride towards innovative treatments for epilepsy, EpilepsyGTx, a pioneering biotechnology firm, has announced a partnership with Viralgen, a prominent contract development and manufacturing organization specializing in gene therapies. This collaboration is geared towards the production of EPY201, a promising investigational gene therapy aimed at tackling focal refractory epilepsy (FRE), a condition that impacts roughly 10 million individuals worldwide, including an estimated 2 million in the United States, United Kingdom, and Europe.

Focal epilepsy is characterized by seizures originating from a specific brain region, and when standard treatment fails after various medications, patients are considered to have refractory epilepsy. The partnership aims to produce EPY201 in preparation for its first human clinical trials, anticipated to commence in early 2027.

The Role of Viralgen's Advanced Manufacturing

Viralgen will utilize its state-of-the-art Aava™ manufacturing platform, reputed for its reliability and efficiency, to ensure the successful production of EPY201. This platform facilitates scalable manufacturing across different AAV serotypes, streamlining the process to deliver high-yield gene therapy products efficiently. To date, Viralgen has successfully generated over 1,500 AAV batches, reinforcing their credibility in the field.

The approach behind EPY201 is innovative; the gene therapy is designed to be delivered directly into the seizure focus of the brain. By focusing its effects locally, EPY201 seeks to diminish the neuronal hyperexcitability that characterizes focal refractory epilepsy. This localized approach promises a minimally invasive solution, eliminating the need for more drastic measures like brain tissue resection or ablation, thus offering patients a chance at seizure freedom.

Comments from Leadership

Nicolas Koebel, Chief Executive Officer of EpilepsyGTx, emphasized the critical nature of this collaboration, stating that Viralgen's expertise in AAV manufacturing and their extensive regulatory experience are essential as they prepare to bring EPY201 closer to clinical implementation. He acknowledged the infrastructure and know-how provided by Viralgen as a significant asset.

Jimmy Vanhove, the CEO of Viralgen, expressed pride in collaborating with EpilepsyGTx and highlighted the efficiency and scalability of their Aava platform as vital for advancing EPY201 for patients in need. Their combined efforts aim to expedite the delivery of this new therapy to those suffering from FRE.

About EpilepsyGTx and Its Innovations

Founded on groundbreaking research from University College London Institute of Neurology in 2021, EpilepsyGTx is devoted to developing cutting-edge therapies that could revolutionize treatment for those with focal refractory epilepsy. Their lead therapy, EPY201, focuses on delivering a gene therapy aimed at ameliorating seizure activity via a targeted intraparenchymal methodology, significantly minimizing potential damage to adjacent brain tissue.

Through rigorous research and support from expert collaborations, EpilepsyGTx aims to bring tangible hope to the millions affected by refractory epilepsy.

Looking Ahead

As the timeline for clinical trials approaches, the collaboration symbolizes a beacon of hope for effectively addressing the needs of those suffering from seizures that resist current medication options. For patients globally, the potential arrival of a novel, minimally invasive treatment could truly transform lives and enhance the standard of care for epilepsy. The journey of EPY201 into clinical studies marks a significant milestone in the quest for more effective epilepsy treatments, combining innovation in biotechnology with dedicated patient care.